166 related articles for article (PubMed ID: 12602762)
21. Fulvestrant: pharmacokinetics and pharmacology.
Robertson JF; Harrison M
Br J Cancer; 2004 Mar; 90 Suppl 1(Suppl 1):S7-10. PubMed ID: 15094758
[TBL] [Abstract][Full Text] [Related]
22. p27(Kip1) induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells.
Carroll JS; Lynch DK; Swarbrick A; Renoir JM; Sarcevic B; Daly RJ; Musgrove EA; Sutherland RL
Cancer Res; 2003 Aug; 63(15):4322-6. PubMed ID: 12907598
[TBL] [Abstract][Full Text] [Related]
23. Research resource: Transcriptional profiling in a cellular model of breast cancer reveals functional and mechanistic differences between clinically relevant SERM and between SERM/estrogen complexes.
Wardell SE; Kazmin D; McDonnell DP
Mol Endocrinol; 2012 Jul; 26(7):1235-48. PubMed ID: 22570330
[TBL] [Abstract][Full Text] [Related]
24. Lead identification of a potent benzopyranone selective estrogen receptor modulator.
McKie JA; Bhagwat SS; Brady H; Doubleday M; Gayo L; Hickman M; Jalluri RK; Khammungkhune S; Kois A; Mortensen D; Richard N; Sapienza J; Shevlin G; Stein B; Sutherland M
Bioorg Med Chem Lett; 2004 Jul; 14(13):3407-10. PubMed ID: 15177442
[TBL] [Abstract][Full Text] [Related]
25. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Baumann CK; Castiglione-Gertsch M
Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
[TBL] [Abstract][Full Text] [Related]
26. A review of selective estrogen receptor modulators in the treatment of breast and endometrial cancer.
Chan S
Semin Oncol; 2002 Jun; 29(3 Suppl 11):129-33. PubMed ID: 12138407
[TBL] [Abstract][Full Text] [Related]
27. Analysis of estrogen agonism and antagonism of tamoxifen, raloxifene, and ICI182780 in endometrial cancer cells: a putative role for the epidermal growth factor receptor ligand amphiregulin.
Gielen SC; Burger CW; Kühne LC; Hanifi-Moghaddam P; Blok LJ
J Soc Gynecol Investig; 2005 Oct; 12(7):e55-67. PubMed ID: 16202921
[TBL] [Abstract][Full Text] [Related]
28. Two antiestrogens affect differently chromatin remodeling of trefoil factor 1 (pS2) gene and the fate of estrogen receptor in MCF7 cells.
Giamarchi C; Chailleux C; Calligé M; Rochaix P; Trouche D; Richard-Foy H
Biochim Biophys Acta; 2002 Oct; 1578(1-3):12-20. PubMed ID: 12393183
[TBL] [Abstract][Full Text] [Related]
29. How is tamoxifen's action subverted?
Jordan VC
J Natl Cancer Inst; 2000 Jan; 92(2):92-4. PubMed ID: 10639501
[No Abstract] [Full Text] [Related]
30. Myometrial effects of selective estrogen receptor modulators on estradiol-responsive gene expression are gene and cell-specific.
Farnell YZ; Ing NH
J Steroid Biochem Mol Biol; 2003 Apr; 84(5):527-36. PubMed ID: 12767277
[TBL] [Abstract][Full Text] [Related]
31. Structural modulation of reactivity/activity in design of improved benzothiophene selective estrogen receptor modulators: induction of chemopreventive mechanisms.
Yu B; Dietz BM; Dunlap T; Kastrati I; Lantvit DD; Overk CR; Yao P; Qin Z; Bolton JL; Thatcher GR
Mol Cancer Ther; 2007 Sep; 6(9):2418-28. PubMed ID: 17876041
[TBL] [Abstract][Full Text] [Related]
32. Nebivolol decreases endothelial cell stiffness via the estrogen receptor beta: a nano-imaging study.
Hillebrand U; Lang D; Telgmann RG; Hagedorn C; Reuter S; Kliche K; Stock CM; Oberleithner H; Pavenstädt H; Büssemaker E; Hausberg M
J Hypertens; 2009 Mar; 27(3):517-26. PubMed ID: 19330906
[TBL] [Abstract][Full Text] [Related]
33. Endometrial effects of selective estrogen receptor modulators (SERMs) on estradiol-responsive gene expression are gene and cell-specific.
Farnell YZ; Ing NH
J Steroid Biochem Mol Biol; 2003 Apr; 84(5):513-26. PubMed ID: 12767276
[TBL] [Abstract][Full Text] [Related]
34. Structure-activity relationships for a family of benzothiophene selective estrogen receptor modulators including raloxifene and arzoxifene.
Overk CR; Peng KW; Asghodom RT; Kastrati I; Lantvit DD; Qin Z; Frasor J; Bolton JL; Thatcher GR
ChemMedChem; 2007 Oct; 2(10):1520-6. PubMed ID: 17654759
[TBL] [Abstract][Full Text] [Related]
35. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents.
Jordan VC
J Med Chem; 2003 Mar; 46(7):1081-111. PubMed ID: 12646017
[No Abstract] [Full Text] [Related]
36. [Specific estrogen receptor modulators (SERMs)].
Trémollières F; Lopes P
Presse Med; 2002 Sep; 31(28):1323-8. PubMed ID: 12355995
[TBL] [Abstract][Full Text] [Related]
37. Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro.
Michael H; Härkönen PL; Kangas L; Väänänen HK; Hentunen TA
Br J Pharmacol; 2007 Jun; 151(3):384-95. PubMed ID: 17420779
[TBL] [Abstract][Full Text] [Related]
38. The clinical relevance of endocrine-therapy-induced changes in lipid metabolism in breast cancer patients.
Frassoldati A; Guarneri V; Conte P
Cancer Biol Ther; 2009 Aug; 8(15):1456-8. PubMed ID: 19617703
[No Abstract] [Full Text] [Related]
39. Genome-wide transcriptional regulation of estrogen receptor targets in fallopian tube cells and the role of selective estrogen receptor modulators.
Moyle-Heyrman G; Schipma MJ; Dean M; Davis DA; Burdette JE
J Ovarian Res; 2016 Feb; 9():5. PubMed ID: 26879975
[TBL] [Abstract][Full Text] [Related]
40. Selective estrogen receptor modulators: tissue selectivity and differential uterine effects.
Silfen SL; Ciaccia AV; Bryant HU
Climacteric; 1999 Dec; 2(4):268-83. PubMed ID: 11910661
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
